Trial · NCT06433050
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events | Through study completion, 28 weeks | Adverse event reporting |
| Primary | Intracavitary obstruction | Through study completion, 28 weeks | Intracavitary left ventricular pressure gradient in mmHg |
| Primary | Cardiac rhythm | Through study completion, 28 weeks | New occurrence of cardiac arrhythmia measured by ambulatory monitoring |
| Primary | Maximal exercise capacity | Through study completion, 28 weeks | Peak oxygen consumption in mL/min |
| Primary | Submaximal exercise capacity | Through study completion, 28 weeks | Stroke volume augmentation at exercise steady state in mL/min |
| Secondary | Systolic function | Through study completion, 28 weeks | Left ventricular ejection fraction in % measured by echocardiography |
| Secondary | Contractility | Through study completion, 28 weeks | Global longitudinal strain in % measured by echocardiography |
| Secondary | Diastolic function | Through study completion, 28 weeks | E/E' ratio measured by echocardiography |
| Secondary | Left ventricular hypertrophy | Through study completion, 28 weeks | Maximal left ventricular wall thickness in mm by echocardiography |
| Secondary | Symptom scores | Through study completion, 28 weeks | Kansas City Living with Heart Failure (KCCQ) Clinical Summary Score, scale 0-100 with lower scores being worse |
| Secondary | Symptom scores and quality of life | Through study completion, 28 weeks | Kansas City Living with Heart Failure (KCCQ) Overall Summary Score, score 0-100 with lower scores being worse |
| Secondary | Biomarkers | Through study completion, 28 weeks | Serum levels of N-terminal-proBNP |
| Secondary | Circulating metabolites | Through study completion, 28 weeks | Concentration of serum metabolites |
| Secondary | Measurement of periods of activity and rest | Through study completion, 28 weeks | Daily step counts by actigraphy |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06433050/registered